Recent 8-K filings for QNCX

• May 18, 2026 20:20 UTC other_material materiality 0.75 positive item 7.01item 9.01

  Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%

  Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.

• May 18, 2026 13:33 UTC m_and_a materiality 1.00 neutral item 1.01item 5.03item 2.01item 3.02item 5.02item 7.01item 9.01

  Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts

  Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.

• Apr 28, 2026 23:59 UTC other_material materiality 0.30 neutral item 8.01

  Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency

  Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).

• Apr 22, 2026 23:59 UTC leadership materiality 0.30 neutral item 5.02

  Quince Therapeutics appoints June Bray as independent director, expands board to four members

  June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.

• Apr 09, 2026 23:59 UTC other_material materiality 0.40 neutral item 3.03item 5.03item 9.01

  Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026

  Approximately 16.3M shares outstanding post-split; ratio 1-for-10.

• Mar 30, 2026 23:59 UTC debt materiality 0.75 positive item 1.02item 7.01item 9.01

  Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang

  Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.

• Mar 20, 2026 23:59 UTC other_material materiality 0.75 negative item 3.01

  Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods

  Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.

• Feb 12, 2026 23:59 UTC other_material materiality 0.90 negative item 2.02item 8.01

  Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger

  As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.

• Feb 02, 2026 23:59 UTC leadership materiality 0.70 negative item 5.02

  Five directors resign from Quince Therapeutics board effective immediately

  Directors Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray resigned on Jan 30, 2026.

• Jan 29, 2026 23:59 UTC other_material materiality 0.85 negative item 9.01

  Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted

  Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.

• Nov 12, 2025 23:59 UTC earnings materiality 0.70 positive item 2.02item 9.01

  Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data

  Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.

• Oct 17, 2025 23:59 UTC other_material materiality 0.55 negative item 7.01

  Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T

  Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.

• Sep 26, 2025 23:59 UTC debt materiality 0.50 neutral item 1.01item 2.03

  Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026

  Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.

• Aug 11, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M

  Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.

• Jul 16, 2025 23:59 UTC other_material materiality 0.70 positive item 7.01item 8.01item 9.01

  Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026

  Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.

• Jun 13, 2025 23:59 UTC other_material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Quince raises $11.5M in private placement of stock and warrants; management participates

  Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.

• Jun 05, 2025 23:59 UTC other_material materiality 0.30 neutral item 5.07

  Quince Therapeutics shareholders approve reverse stock split and authorized share increase

  Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.70 · Most common event other_material

4 positive 5 negative 8 neutral

source · QNCX on sec.gov